Table of Contents :
• Stock Rating & Target Price
• Investment Thesis
• Fundamental Models Used
• Company Description
• Corporate Timeline
• Key Metrics (KPI ) and Recently Reported Earnings Review
• Business Highlights, Strategic Announcements & Outlook
• Quarter-over-Quarter (Q-o-Q) and Year-over-Year (Y-o-Y) Growth Analysis
• Key Catalysts Driving Growth
• Historical Financial Statement Analysis & CAGR Trends
• Quarterly Key Financial Ratios and Performance Metrics
• Annual Financial Performance Analysis: Horizontal and Vertical Financial Analysis, Trends
• Financial Forecasts
• Annual Forecasts: Income Statement
• Annual Forecasts: Cash Flow Statements
• Net Debt Levels
• A Closer Look at DCF: Our Assumptions and Methodology
• Terminal Value Calculation
• Target Price Analysis
• Valuation Multiples
• Supplementary Valuation Analysis: Multiples Approach
• Scenario/Sensitivity Analysis – Base Case , Bull Case ,Bear Case
• Holistic Peer Review & Trading Comps: Financial Data, Operational Metrics, and Valuation Multiples
• Implied Price Per Share
• Ownership Activity/ Insider Trades
• Ownership Summary
• An analysis of ESG Risk Rating
• Key Professionals
• Key Board Members
• Key Risks Considerations
• Analyst Ratings
• Analyst Industry Views
• Disclosures
Humana Inc (HUM): Core MA Margin Stability Reasserting —Biggest Reasons Behind Why It Raised Guidance While Peers Cut Outlook?
Humana raised its FY25 adjusted EPS outlook to about $17 (from $16.25) as Q2 execution showed stable medical cost trends, disciplined MA pricing, and CenterWell Pharmacy outperformance that offset transitory headwinds from mild weather, timing of O&M spend, and slightly higher interest costs. Individual MA membership losses were revised to ~500K from 550K, with 40% of impacted members re-enrolling and performing in line with expectations, signaling improved retention and pricing adequacy. CenterWell continues to differentiate Humana’s vertically integrated model: pharmacy volumes rose on expanded limited-distribution drug access, while primary care maintained robust patient growth and cost discipline. Management pulled forward $100M of transformation investments (automation, shared services, AI), tempering near-term EPS but supporting medium-term operating leverage. Medicaid growth in Virginia and upcoming Illinois entry further diversify earnings. Unlike peers UNH, CNC, and ELV that cut guidance on elevated utilization and exchange exposure, Humana benefits from a conservative starting point, low ACA reliance, and structurally improving MA economics. With Stars results still a swing factor, will CenterWell’s earnings durability and tighter MA cost control sustain Humana’s premium growth profile as sector pressures persist into 2026?
